Aftab Mahmood

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 44 citations

Hematological Malignancy, Oncology, Transplantation +8

Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders

Aftab Mahmood, Donata Sodano, Anthony Dash et al. · Journal of Clinical Apheresis · 2005 · 27 citations

Dialysis, Immunology, Dialysis Therapy +16

Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study

Ignacio Durán, M. Fink, Amit Bahl et al. · European Journal of Cancer Care · 2016 · 24 citations

Surgical Oncology, Cancer Management, Epidemiology Of Cancer +17